Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 23, 2014

AbbVie buys active pharmaceutical ingredient (API) facility in Singapore

US-based AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Tuas Biomedical Park, Singapore.

US-based AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Tuas Biomedical Park, Singapore.

AbbVie intends to expand global operations of small molecule and biologics manufacturing.

The 120,000ft² site will help the company to increase capacity for compounds within its immunology and oncology pipelines.

AbbVie operations senior vice-president Azita Saleki-Gerhardt said: "The Singapore site will help to strengthen our global manufacturing capabilities, offering a higher degree of flexibility and scale.

"The facility will support new technologies and the growth of our pipeline in immunology and oncology, helping us to address significant unmet medical needs for patients around the world."

"The facility will support new technologies and the growth of our pipeline in immunology and oncology, helping us to address significant unmet medical needs for patients around the world."

The site is the firm’s first manufacturing facility in Asia and features a contained API facility, additional buildings and ancillary equipment.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

According to AbbVie, the API facility is expected to commence operations in 2016.

The company will also build a bulk biologics manufacturing facility at the site, confirmed by an announcement in February. It is expected to be operational in 2019.

Singapore Economic Development Board biomedical sciences and consumer businesses executive director Kevin Lai said: "Singapore offers a neutral and trusted location for pharmaceutical companies to orchestrate and expand their operations across the region."

The firm’s operations in Asia include R&D functions in Tokyo, Japan and Shanghai, China, as well as commercial operations across the region.

With the latest addition, AbbVie’s manufacturing network increases to thirteen sites, located in the US, Europe, Asia and Puerto Rico. It also holds strategic partnerships with third-party manufacturers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU